Telemetry Investments L.L.C. grew its stake in Affimed NV (NASDAQ:AFMD) by 127.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 425,398 shares of the biopharmaceutical company’s stock after purchasing an additional 238,719 shares during the period. Affimed makes up about 0.8% of Telemetry Investments L.L.C.’s portfolio, making the stock its 24th biggest position. Telemetry Investments L.L.C.’s holdings in Affimed were worth $1,323,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors also recently bought and sold shares of the company. FMR LLC purchased a new position in Affimed during the 3rd quarter worth $5,552,000. Stonepine Capital Management LLC purchased a new position in Affimed during the 4th quarter worth $2,221,000. Lindbrook Capital LLC purchased a new position in Affimed during the 4th quarter worth $38,000. Sio Capital Management LLC purchased a new position in Affimed during the 3rd quarter worth $2,426,000. Finally, Prescott Group Capital Management L.L.C. purchased a new position in Affimed during the 3rd quarter worth $714,000. 41.07% of the stock is owned by institutional investors and hedge funds.
Several research analysts have commented on the company. BidaskClub upgraded Affimed from a “sell” rating to a “hold” rating in a report on Tuesday, November 20th. ValuEngine downgraded Affimed from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th. Finally, Zacks Investment Research upgraded Affimed from a “sell” rating to a “hold” rating in a report on Thursday, January 3rd. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $4.81.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by WKRB News and is owned by of WKRB News. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.wkrb13.com/2019/03/15/telemetry-investments-l-l-c-has-1-32-million-stake-in-affimed-nv-afmd.html.
Affimed Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Further Reading: Book Value Per Share in Stock Trading
Want to see what other hedge funds are holding AFMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Affimed NV (NASDAQ:AFMD).
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.